These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 9886093)
1. Evidence for the sequential formation of two complexes between an uptake inhibitor, GBR 12783 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine], and the neuronal transporter of dopamine. Do-Régo JC; Hue H; Costentin J; Bonnet JJ J Neurochem; 1999 Jan; 72(1):396-404. PubMed ID: 9886093 [TBL] [Abstract][Full Text] [Related]
2. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Héron C; Costentin J; Bonnet JJ Eur J Pharmacol; 1994 Nov; 264(3):391-8. PubMed ID: 7698180 [TBL] [Abstract][Full Text] [Related]
3. Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Xu C; Coffey LL; Reith ME Biochem Pharmacol; 1995 Jan; 49(3):339-50. PubMed ID: 7857321 [TBL] [Abstract][Full Text] [Related]
4. Complex ionic control of [3H]GBR 12783 binding to the dopamine neuronal carrier. Héron C; Billaud G; Costentin J; Bonnet JJ Eur J Pharmacol; 1996 Apr; 301(1-3):195-202. PubMed ID: 8773464 [TBL] [Abstract][Full Text] [Related]
5. Specific binding of [3H]GBR 12783 to the dopamine neuronal carrier included in polarized membranes. Billaud G; Costentin J; Bonnet JJ Eur J Pharmacol; 1993 Nov; 247(3):333-40. PubMed ID: 8307105 [TBL] [Abstract][Full Text] [Related]
6. Interaction of two sulfhydryl reagents with a cation recognition site on the neuronal dopamine carrier evidences small differences between [3H]GBR 12783 and [3H]cocaine binding sites. Refahi-Lyamani F; Saadouni S; Costentin J; Bonnet JJ Naunyn Schmiedebergs Arch Pharmacol; 1995 Feb; 351(2):136-45. PubMed ID: 7770096 [TBL] [Abstract][Full Text] [Related]
8. Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the rat. Régo JC; Syringas M; Leblond B; Costentin J; Bonnet JJ Br J Pharmacol; 1999 Sep; 128(1):51-60. PubMed ID: 10498834 [TBL] [Abstract][Full Text] [Related]
9. Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. Matecka D; Lewis D; Rothman RB; Dersch CM; Wojnicki FH; Glowa JR; DeVries AC; Pert A; Rice KC J Med Chem; 1997 Feb; 40(5):705-16. PubMed ID: 9057857 [TBL] [Abstract][Full Text] [Related]
10. Effect of CH3HgCl and several transition metals on the dopamine neuronal carrier; peculiar behaviour of Zn2+. Bonnet JJ; Benmansour S; Amejdki-Chab N; Costentin J Eur J Pharmacol; 1994 Jan; 266(1):87-97. PubMed ID: 8137886 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909). Zhang Y; Rothman RB; Dersch CM; de Costa BR; Jacobson AE; Rice KC J Med Chem; 2000 Dec; 43(25):4840-9. PubMed ID: 11123994 [TBL] [Abstract][Full Text] [Related]
12. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). Matecka D; Rothman RB; Radesca L; de Costa BR; Dersch CM; Partilla JS; Pert A; Glowa JR; Wojnicki FH; Rice KC J Med Chem; 1996 Nov; 39(24):4704-16. PubMed ID: 8941383 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Pristupa ZB; Wilson JM; Hoffman BJ; Kish SJ; Niznik HB Mol Pharmacol; 1994 Jan; 45(1):125-35. PubMed ID: 8302271 [TBL] [Abstract][Full Text] [Related]
14. Photoaffinity labeling of the dopamine reuptake carrier protein with 3-azido[3H]GBR-12935. Berger SP; Martenson RE; Laing P; Thurkauf A; Decosta B; Rice KC; Paul SM Mol Pharmacol; 1991 Apr; 39(4):429-35. PubMed ID: 2017146 [TBL] [Abstract][Full Text] [Related]
15. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Niznik HB; Tyndale RF; Sallee FR; Gonzalez FJ; Hardwick JP; Inaba T; Kalow W Arch Biochem Biophys; 1990 Feb; 276(2):424-32. PubMed ID: 2306106 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo characterization of newly developed iodinated 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]piperazine derivatives in rats: limited value as dopamine transporter SPECT ligands. Rijks LJ; Booij J; Doornbos T; Boer GJ; Ronken E; de Bruin K; Vermeulen RJ; Janssen AG; Van Royen EA Synapse; 1996 Jul; 23(3):201-7. PubMed ID: 8807748 [TBL] [Abstract][Full Text] [Related]
17. Thermodynamics of the binding of BTCP (GK 13) and related derivatives on the dopamine neuronal carrier. Billaud G; Menard JF; Marcellin N; Kamenka JM; Costentin J; Bonnet JJ Eur J Pharmacol; 1994 Aug; 268(3):357-63. PubMed ID: 7805759 [TBL] [Abstract][Full Text] [Related]
18. In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [3H]GBR 12783. Vaugeois JM; Bonnet JJ; Costentin J Eur J Pharmacol; 1992 Jan; 210(1):77-84. PubMed ID: 1350989 [TBL] [Abstract][Full Text] [Related]
19. Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter. Dutta AK; Xu C; Reith ME J Med Chem; 1998 Aug; 41(17):3293-7. PubMed ID: 9703474 [TBL] [Abstract][Full Text] [Related]
20. Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Hiroi T; Imaoka S; Chow T; Yabusaki Y; Funae Y Biochem Pharmacol; 1997 Jun; 53(12):1937-9. PubMed ID: 9256169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]